Abstract:Cancer is a perilous life-threatening disease, and attempts are constantly made to create multinuclear transition metal complexes that could lead to potential anticancer medications and administration procedures. Hence, this work aims to design, synthesize, characterize, and assess the anticancer efficacy of ruthenium p-cymene complexes incorporating N, N'- bis(4-substituted benzoyl)hydrazine ligands. The formation of the new complexes (Ru2H1-Ru2H3) has been thoroughly established by elemental analysis, FT-IR, UV-vis, NMR, and HR-MS spectral techniques. The solid-state molecular structures of the complexes Ru2H1 and Ru2H3 have been determined using the SC-XRD study, which confirms the N, O, and Cl-legged piano stool pseudo-octahedral geometry on each ruthenium(II) ion. The stability of these complexes in the solution state and their lipophilicity profile have been determined. Further, the titled complexes were tested for their in vitro anticancer activity against the cancerous H460 (lung cancer cells), SkBr3 (breast cancer cells), HepG2 (liver cancer cells), and Hela (cervical cancer cells) along with non-cancerous (HEK-293) cells. The IC50 results revealed that complex Ru2H3 exhibits potent activity against the proliferation of all four cancer cells and outscored the effect of standard metallodrug cisplatin. This may be attributed to the presence of a couple of lipophilic electron-donating methoxy groups in the ligand scaffold and also the ruthenium(II) p-cymene motifs. Advantageously, all the complexes (Ru2H1-Ru2H3) displayed cytotoxic specificity only towards the cancerous cell by leaving the off-target non-cancerous cells undamaged. Acridine orange/ethidium bromide (AO/EB) staining, Hoechst 33342, Mitochondrial Membrane Potential (MMP), and Reactive Oxygen Species (ROS) staining assays were used to investigate the apoptotic pathway and ROS levels in mitochondria. The results of Western blot analysis confirmed that complexes triggered apoptosis through intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 proteins. Finally, the extent of apoptosis triggered by complex (Ru2H3) was quantified with the aid of flow cytometry using the Annexin V-FITC/propidium iodide (PI) double-staining technique.

Nuclear permeable ruthenium(II) β-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis.

Lysosome-targeted ruthenium(II) complexes induce both apoptosis and autophagy in HeLa cells

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Antitumor studies evaluation of triphenylphosphine ruthenium complexes with 5,7-dihalo-substituted-8-quinolinoline targeting mitophagy pathways

Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Inoperable brain metastases from non-small cell lung cancer: what part does whole brain radiotherapy play in standard treatment?

Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Fluorescence cystoscopy: is flexible scope as effective as rigid?

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Nanoscaled Carborane Ruthenium(ii)-Arene Complex Inducing Lung Cancer Cells Apoptosis

Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis

Potent half-sandwich Ru(II) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene.

Three Ru(II) complexes modulate the antioxidant transcription factor Nrf2 to overcome cisplatin resistance

DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer Cells

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Ruthenium Complexes as Promising Candidates against Lung Cancer

Eye-position signals in successive saccades

Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway